関節リウマチ, 間性関節炎, 体軸型脊椎関節炎患者におけるBMIの生物製剤/分子標的DMARDsに対する影響. システマティックレビュー
Autoimmunity Reviews 22 (2023) 103357
The study demonstrated that obesity is a factor that could play a role in treatment decision-making in people living with inflammatory arthritis (IA). It appears that efficacy of TNFi is affected by patients’ weight/BMI in all forms of IA, while this is not the case for TCZ and ABA in RA, as well for IL-17 and IL-23 inhibitors in PsA.